NMN vs NR: which NAD+ booster has the better evidence?
Neither is proven to extend human life, but nicotinamide riboside has the better-documented, independently scrutinized NAD+ data, while NMN's benefit evidence is sparser and more sponsor-bound; both share the same fatal gap of never measuring aging itself.
How they compare
NMN and nicotinamide riboside are the two headline NAD+ boosters, and people compare them for the same reason: both are precursors the body converts into NAD+, the coenzyme that fuels cellular energy and repair enzymes like the sirtuins. NAD+ falls with age, so both are sold on the same promise, top the marker back up and slow the metabolic slide of aging. The pitch, the mechanism, and the marketing overlap almost completely.
The key difference the evidence reveals is not whether they work but how cleanly the NAD+ half is documented. For nicotinamide riboside, every human RCT shows a reliable, dose-dependent rise in blood NAD+, and an independent University of Copenhagen review provides a genuine counterweight. NMN's benefit data are thinner and more conflicted, leaning on three sponsor-funded trials. Neither has ever had its effect on human lifespan measured.
The table
| Dimension | NMN | Nicotinamide riboside |
|---|---|---|
| What it targets | Raises NAD+ as a precursor, pitched to reactivate sirtuins and slow aging | Raises NAD+ as a vitamin-B3 form, same sirtuin and mitochondrial rationale |
| Human evidence | Three RCTs report benefits; NAD+ rises, but downstream outcomes are mostly unmoved | Every RCT shows blood NAD+ rises dose-dependently (>2-fold, p<0.001); downstream trials small, short, mostly null |
| Size of the effect | Marker goes up in weeks; ordinary health outcomes largely unchanged | Reliable blood NAD+ rise, but muscle NAD+ did not rise (210 vs 197 pmol/mg, p=0.22) |
| Funding and conflicts | The three benefit RCTs funded by Mitsubishi, which supplied NMN and employed authors; Sinclair co-founded NMN companies | ChromaDex supplied NR for most trials and its CSO holds patents, but an independent 2023 review found very few clinically relevant effects |
| Best understood as | A plausible, sponsor-heavy marker-mover whose 'reverses aging' framing tips into misleading | A safe vitamin-B3 derivative that genuinely raises blood NAD+, oversold once bundled with 'slows aging' |
People also ask
- Is NMN or NR better?
- Neither is proven to extend life. NR has the cleaner evidence: every human trial shows a reliable, dose-dependent blood NAD+ rise, plus an independent review as a counterweight. NMN's benefit data lean on three trials funded by the company selling it.
- Do either of them actually make you live longer?
- No. Both reliably raise blood NAD+ within weeks, but no human trial has ever measured lifespan, healthspan, or any validated aging endpoint for either compound. Raising a marker is not the same as living longer, the recurring gap across NAD+ science.
- Can I trust the studies behind them?
- Read the funding. NMN's three benefit trials were funded by Mitsubishi, which supplied the compound. Most NR trials used ChromaDex-supplied material, though an independent Copenhagen review pushed back and found very few clinically relevant effects.
The honest read
Both raise blood NAD+, look safe short-term, and have never been shown to extend a human life. If forced to choose on evidence quality alone, NR's NAD+ data are better documented and independently checked, but neither earns the anti-aging label.
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.